SURTECO GROUP SE

  • WKN: 517690
  • ISIN: DE0005176903
  • Land: Deutschland

Analyst Coverage

Datum Institute Analyst Empfehlung Download
1 November 2021 Sphene Capital Hasler Buy Download
29 October 2021 Pareto Securities Hinkel Buy Download
19 October 2021 Pareto Securities Hinkel Buy Download
3 August 2021 Pareto Securities Hinkel Buy Download
2 August 2021 Sphene Capital Hasler Buy Download
15 July 2021 Sphene Capital Hasler Buy Download
25 June 2021 Pareto Securities Hinkel Buy Download
3 May 2021 Sphene Capital Hasler Buy Download
3 May 2021 Pareto Securities Hinkel Buy Download
29 January 2021 Sphene Capital Hasler Buy Download
20 November 2020 Pareto Securities Hinkel Buy Download
16 November 2020 Hauck & Aufhäuser Sandherr Buy Download
16 November 2020 Sphene Capital Hasler Buy Download
13 November 2020 Pareto Securities Hinkel Buy Download
14 August 2020 Hauck & Aufhäuser Sandherr Hold Download
13 August 2020 Sphene Capital Hasler Buy Download
12 August 2020 Pareto Securities Hinkel Buy Download
20 May 2020 Hauck & Aufhäuser Sandherr Hold Download
15 May 2020 Sphene Capital Hasler Buy Download

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben

30. November 2021, 16:02

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021